Search results
Results from the WOW.Com Content Network
6β-Naltrexol, or 6β-hydroxynaltrexone (developmental code name AIKO-150), is a peripherally-selective opioid receptor antagonist related to naltrexone. [2] [3] It is a major active metabolite of naltrexone formed by hepatic dihydrodiol dehydrogenase enzymes.
Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. [8] It has also been found effective in the treatment of other addictions and may be used for them off-label. [12]
Low-dose naltrexone has been studied for the treatment of multiple chronic pain disorders including fibromyalgia, multiple sclerosis, Crohn’s disease, and complex regional pain syndrome. [ 2 ] Naltrexone is approved by the Food and Drug Administration (FDA) for medication-assisted treatment of alcoholism and opioid use disorders . [ 3 ]
This includes the group administered Naglieri Nonverbal Ability Test - Second Edition and the Naglieri Nonverbal Ability Test - Online version. The most current version is NNAT3. [ 1 ] Like all nonverbal ability tests, the NNAT is intended to assess cognitive ability independently of linguistic and cultural background.
The Millon Clinical Multiaxial Inventory – Fourth Edition (MCMI-IV) is the most recent edition of the Millon Clinical Multiaxial Inventory.The MCMI is a psychological assessment tool intended to provide information on personality traits and psychopathology, including specific mental disorders outlined in the DSM-5.
In contrast, standard fixed tests almost always provide the best precision for test-takers of medium ability and increasingly poorer precision for test-takers with more extreme test scores. [citation needed] An adaptive test can typically be shortened by 50% and still maintain a higher level of precision than a fixed version. [2]
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. [4] [6] It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. [4]
(+)-Naloxone (dextro-naloxone) is a drug which is the opposite enantiomer of the opioid antagonist drug (−)-naloxone.Unlike (−)-naloxone, (+)-naloxone has no significant affinity for opioid receptors, [1] but instead has been discovered to act as a selective antagonist of Toll-like receptor 4.